RECALIBRATING GAVI 5.0 IN LIGHT OF COVID-19 AND SUCCESSFUL REPLENISHMENT
The Board set a new ambition for Gavi 5.0 in the context of SDGs
World leaders reaffirmed commitment to Gavi’s mission amid a pandemic

- COVID-19 has made Gavi 5.0 goals even more relevant
- Successful replenishment offers an opportunity to adequately finance critical priorities
- US$ 8.8 billion raised for 2021-25 of which US$ 1.6 billion is yet to be programmed
While Gavi 5.0 goals remain relevant, a few priorities would need recalibration

1. **Introduce and Scale up Vaccines**
   - Pacing introduction of new vaccines
   - Delivering COVID-19 vaccines

2. **Strengthen Health Systems to Increase Equity in Immunisation**
   - Preventing backsliding
   - Rebuilding better with a focus on Zero dose children

3. **Improve Sustainability of Immunisation Programmes**
   - Safeguarding domestic financing
   - Strategic engagement with Middle Income Countries
Zero dose children representing acute inequities are at the heart of Gavi 5.0

Nearly 50% of children dying of vaccine preventable diseases in Gavi-supported countries are Zero dose

- 47% less likely to have a mother who received antenatal care
- 47% less likely to have a mother who had an institutional delivery
- 33% less likely to live in a household with water and cleansing agents
COVID-19 is exacerbating inequities and could increase the number of Zero dose children.
Successfully reaching Zero dose children will require:

- Dedicated financing for equity
- Differentiated approaches
- Context specific, local partnerships
- Community engagement
- Intersectoral collaboration
- Innovation
Gavi 4.0 has launched promising approaches that can now be scaled up

**IDENTIFY**
- Who, where, why, how many Zero dose children

**ADVOCATE**
- Use evidence to make a case for political attention and resources

**REACH**
- Flexible, integrated approaches that address both supply and demand side barriers

**MONITOR & MEASURE**
- Monitor real time
- Measure outcomes
- Learn to improve

Locations included:
- Pakistan
- Afghanistan
- Rwanda
- Kenya
Dedicated financing creates further momentum to identify and reach Zero dose children

- Current HSS allocation lower in Gavi 5.0, despite increased ambition on equity
- Reaching Zero dose children is highly beneficial though more complex and costly
- Countries pivoting towards maintaining, restoring and strengthening immunisation services
- Need early assurance on funding available for Zero dose

Request: US$ 500 million increase (US$ 1.7 billion) ~20% increase on Gavi 4.0
Additional financing will be needed for other critical priorities

**INDICATIVE RANGE**

<table>
<thead>
<tr>
<th>Priority</th>
<th>Indicative Range (US$ million)</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19 delivery</td>
<td>150</td>
</tr>
<tr>
<td>Innovation</td>
<td>150-250</td>
</tr>
<tr>
<td>VPD surveillance</td>
<td>75-100</td>
</tr>
<tr>
<td>Partners Engagement Framework</td>
<td>148-157</td>
</tr>
<tr>
<td>Secretariat Capacity</td>
<td>84-112</td>
</tr>
<tr>
<td>Fiduciary risk assurance</td>
<td>75-125</td>
</tr>
<tr>
<td>India Strategy</td>
<td>200-250</td>
</tr>
</tbody>
</table>

**For decision tomorrow**

**For high level guidance**

- Are these the right priorities?
- Is the level of investments appropriate?
- Are any priorities missing?
Board is requested to:

- Provide guidance on recalibrated priorities and level of investments
- Approve an additional US$ 500 million in HSS allocation as dedicated funding for Zero dose children
- Approve the carry-forward of an amount of US$ 85 million in co-financing waivers and CEO authority to 2021
Recommendation (1/2)

The Gavi Alliance Board is requested to:

a) **Provide guidance** on the recalibration of programmatic priorities and how they reflect appropriate trade-offs in light of COVID-19 and the successful replenishment;

b) **Approve** an additional US$ 500 million to the HSS allocation of US$ 1.2 billion for the strategic period 2021-2025 as dedicated funding for zero-dose children and missed communities. This amount is in addition to the funding amounts included in the forecast presented and previously approved by the Board at its July 2020 meeting;

c) **Approve** the carry-forward of an amount of US$ 85 million in co-financing waivers and extend to 2021 the authority granted by the Board in May 2020 to waive 2020 co-financing obligations on a case-by-case basis upon request from a country;
**Recommendation (2/2)**

d) **Note** that US$ 500 to 675 million may be required in 2021-2025 for innovation, vaccine-preventable disease (VPD) surveillance, the strategic partnership with India, and fiduciary risk assurance and financial management capacity, and will be brought back to the Board for decision in due course per guidance provided at the September 2020 Board meeting;

e) **Note** that to deliver on the recalibrated priorities an increase in PEF spending in the order of US$ 148 to 157 million may be required, and that the details of this request will be brought to the upcoming meetings; and

f) **Note** that additional Secretariat resources of approximately US$ 84 to 112 million may be required in 2021-2025, to be confirmed by the ongoing Organisational Review, and would be brought back to the October 2020 AFC and December 2020 Board meetings respectively.